NASDAQ$SDGR
Schrodinger Inc/United States · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported strong fourth quarter results, highlighted by a 55 percent increase in software revenue compared to the same period last year.
Schrödinger reported a strong fourth quarter, with software revenue increasing by 55% compared to the fourth quarter of 2020. The company's total revenue for the quarter was $46.2 million, a 40% increase year-over-year. Schrödinger also provided its financial outlook for 2022 and outlined key strategic goals for 2022-2023.
- Software revenue increased by 55% compared to the fourth quarter of 2020.
- Total revenue increased by 40% year-over-year.
- Gross profit increased by 39% year-over-year.
- Company expects to initiate its first Phase 1 clinical study of its MALT1 inhibitor in patients with relapsed and resistant lymphoma later this year.
Headline financials
Revenue & EPS history
Schrodinger · Revenue · Quarterly
$46.2M
Revenue by segment
Schrodinger · $13.7M total across 1 segment · Q3 2023
- Drug Discovery$13.7M+11.3%100.0%
Forward guidance
Schrödinger provided financial outlook for the fiscal year ending December 31, 2022.
Tailwinds
- Total revenue expected to range from $161 million to $181 million, representing 17 percent to 31 percent growth over 2021
- Total software revenue expected to range from $126 million to $136 million, representing 11 percent to 20 percent growth over 2021
- Total drug discovery expected to range from $35 million to $45 million, representing 42 to 82 percent growth over 2021
- Operating expense growth is expected to be slightly lower than the 42 percent reported for the year ended December 31, 2021
- Software gross margin percentage is expected to be in the mid-70s
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
-2.2%
Avg return
Earnings day
-1.6%
Avg return
5 days after
+1.8%
Avg return
30 days after
42%
11 / 26 earnings
Positive
+31.4%
Q4 2021
Best reaction
-29.9%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.2% | +1.9% | +23.0% | |
| Q4 2025 | +8.3% | +5.9% | -6.1% | |
| Q3 2025 | -5.8% | -7.4% | -10.8% | |
| Q1 2025 | +0.6% | +0.2% | +3.8% | |
| Q4 2024 | +2.5% | -2.9% | -8.0% | |
| Q3 2024 | +13.1% | -5.1% | +7.8% | |
| Q2 2024 | +0.1% | -15.7% | -6.8% | |
| Q1 2024 | -4.9% | -1.4% | -11.7% | |
| Q4 2023 | -23.1% | -23.7% | -18.4% | |
| Q3 2023 | +15.3% | +27.5% | +49.7% | |
| Q2 2023 | -26.9% | -27.3% | -29.8% | |
| Q1 2023 | -5.1% | -6.4% | +22.3% | |
| Q4 2022 | +14.5% | +21.7% | +16.8% | |
| Q3 2022 | -14.6% | -15.6% | -29.2% | |
| Q2 2022 | +1.5% | -4.9% | -19.1% | |
| Q1 2022 | -5.5% | -10.5% | +1.5% | |
| Q4 2021 | +31.4% | +45.4% | +36.4% | |
| Q3 2021 | -16.1% | -15.6% | -31.6% | |
| Q2 2021 | -5.1% | -12.1% | -0.1% | |
| Q1 2021 | -6.8% | -4.3% | +19.4% | |
| Q4 2020 | -29.9% | -29.7% | -20.8% | |
| Q3 2020 | +12.4% | +15.8% | +39.6% | |
| Q3 2019 | +12.4% | +15.8% | +39.6% | |
| Q2 2020 | -2.5% | -2.4% | -24.2% | |
| Q1 2020 | -8.1% | +0.5% | +3.0% | |
| Q4 2019 | -14.6% | +8.3% | +1.5% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro